• Exchange: ASE
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

CSL:AU

74.8100 AUD 0.5100 0.69%

As of 22:12:52 ET on 09/01/2014.

Snapshot for CSL Ltd (CSL)

Open: 74.0100 Day's Range: 74.0100 - 74.8200 Volume: 179,557
Previous Close: 74.3000 52wk Range: 63.7700 - 74.9700 1-Yr Rtn: +10.02%

Stock Chart for CSL

No chart data available.
  • CSL:AU 74.8200
  • 1D
  • 1M
  • 1Y
74.3000
Interactive CSL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CSL

Current P/E Ratio (ttm) 25.6952
Estimated P/E(06/2015) 22.3154
Relative P/E vs. AS51 1.3245
Earnings Per Share (USD) (ttm) 2.7014
Est. EPS (USD) (06/2015) 3.1210
Est. PEG Ratio 1.7636
Market Cap (M AUD) 35,461.63
Shares Outstanding (M) 475.84
30 Day Average Volume 1,678,695
Price/Book (mrq) 10.4457
Price/Sale (ttm) 6.3083
Dividend Indicated Gross Yield 1.66%
Cash Dividend (AUD) 0.6485
Dividend Ex-Date 09/08/2014
5 Year Dividend Growth 16.93%
Next Earnings Announcement 02/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CSL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CSL

CSL Limited develops, manufactures and markets human pharmaceutical and diagnostic products derived from human plasma. The Company's products include pediatric and adult vaccines, infection and pain medicine, skin disorder remedies, antivenoms, anticoagulants and immunoglobulins.

John ShineChairmanHan Willem KottermanVice Chairman
Paul PerreaultCEO/Managing DirectorGordon NaylorChief Financial Officer
More Company Profile & Key Executives for CSL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil